Tianjin Acelbio Develop Resveratrol for Pharmaceutical
date：2012-05-29
browse：（457）
Keyword：
Recently, the Biopharmaceutical Industry Development Plan in Tianjin Binhai New Area (2011-2020) "(hereinafter referred to as the" Plan ") is formally released. According to reports, the Binhai New Area government has gradually established bio-medicine industry chain of "Innovation - Incubation - Test – Production" and exerts every effort to enhance the development of new drugs. Binhai New Area should integrate effective resources in the biomedical field, and encourage local enterprises and R & D institutions to adopt the international standards for certification, so as to promote the bio-medicine towards transformation from "imitation" into "innovation" and international developmentl.
Liu Xiaozhong, executive vice president of WuXi PharmaTech Co., Ltd., said: "In recent years, a group of competitive enterprises with strong competitive strength has grown up in the biomedical field of the Binhai New Area. With the expiration of patent of the main drugs in the developed countries, the industry of generic drug and new drug in Binhai New Area will usher in a new era”. For example, "mesenchymal stem cell injection", a kind of stem cell therapy drug that has used in clinical trials for the first time in the world and has enjoyed its rights of independent research and development; Sifuvirtide, the fourth generation of anti-AIDS drugs that independently developed; "Circular Permuted Tumor Necrosis Factor Related Apoptosis Inducing Ligand (CPT)", a kind of drug used for the treatment of myeloma, and "cells of Mycobacterium smegmatis vaccine", a kind of drug used for the prevention of tuberculosis. And a number of innovative drugs have been used in the stage of clinical testing.
According to reports, the biomedical industry base in Binhai New Area has gathered nearly 100 domestic and international famous bio-pharmaceutical manufacturing enterprises and incubators in the park, including Asymchem Laboratories, Novo Nordisk, Novozymes, GlaxoSmithKline, Servier and Tianjin Kingyork Group. This area has gathered over 50% of biotechnology and pharmaceutical companies in Tianjin. The scale of the industry has improved rapidly with an average annual growth rate of 40%.
Professor Zhang Wei, Chief Scientist of Tianjin Acelbio Co., Ltd., said: "we have been successfully finished the project of large-scale nurturing 200 liters of resveratrol for pharmaceutical in the plant cells and expanding the production of it, and pass acceptance test of Tianjin Science and Technology Commission.” The core product of this project is resveratrol which prevents arterial atherosclerosis, coronary heart disease and other diseases. The users of such products have reached about 200 million in the world, and increase at the annual average rate of 50 million. And its sales volume is expected to exceed RMB100 million if the project has realized industrialization.
According to reports, with a group of high-level R & D institutions have settled in Binhai New Area such as Tianjin International Joint Academy of Biotechnology & Medicine, Academy of Military Medical Sciences, Chinese Academy of Sciences of Industrial Biotechnology R & D Center, and National Stem Cell Engineering Technology Research Center, service of biomedical industry in Binhai New Area has been further improved. For instance, Tianjin International Joint Academy of Biotechnology & Medicine had conducted 59 kinds of new drugs’ research and development, including 23 kinds of drugs of the first level last year, and obtained 5 certificates for new drugs and 19 new drugs’ approval documents for clinical research. 9 clinical projects have been approved by experts and are put into industrial production.
Copyright:Herbridge Media
Liu Xiaozhong, executive vice president of WuXi PharmaTech Co., Ltd., said: "In recent years, a group of competitive enterprises with strong competitive strength has grown up in the biomedical field of the Binhai New Area. With the expiration of patent of the main drugs in the developed countries, the industry of generic drug and new drug in Binhai New Area will usher in a new era”. For example, "mesenchymal stem cell injection", a kind of stem cell therapy drug that has used in clinical trials for the first time in the world and has enjoyed its rights of independent research and development; Sifuvirtide, the fourth generation of anti-AIDS drugs that independently developed; "Circular Permuted Tumor Necrosis Factor Related Apoptosis Inducing Ligand (CPT)", a kind of drug used for the treatment of myeloma, and "cells of Mycobacterium smegmatis vaccine", a kind of drug used for the prevention of tuberculosis. And a number of innovative drugs have been used in the stage of clinical testing.
According to reports, the biomedical industry base in Binhai New Area has gathered nearly 100 domestic and international famous bio-pharmaceutical manufacturing enterprises and incubators in the park, including Asymchem Laboratories, Novo Nordisk, Novozymes, GlaxoSmithKline, Servier and Tianjin Kingyork Group. This area has gathered over 50% of biotechnology and pharmaceutical companies in Tianjin. The scale of the industry has improved rapidly with an average annual growth rate of 40%.
Professor Zhang Wei, Chief Scientist of Tianjin Acelbio Co., Ltd., said: "we have been successfully finished the project of large-scale nurturing 200 liters of resveratrol for pharmaceutical in the plant cells and expanding the production of it, and pass acceptance test of Tianjin Science and Technology Commission.” The core product of this project is resveratrol which prevents arterial atherosclerosis, coronary heart disease and other diseases. The users of such products have reached about 200 million in the world, and increase at the annual average rate of 50 million. And its sales volume is expected to exceed RMB100 million if the project has realized industrialization.
According to reports, with a group of high-level R & D institutions have settled in Binhai New Area such as Tianjin International Joint Academy of Biotechnology & Medicine, Academy of Military Medical Sciences, Chinese Academy of Sciences of Industrial Biotechnology R & D Center, and National Stem Cell Engineering Technology Research Center, service of biomedical industry in Binhai New Area has been further improved. For instance, Tianjin International Joint Academy of Biotechnology & Medicine had conducted 59 kinds of new drugs’ research and development, including 23 kinds of drugs of the first level last year, and obtained 5 certificates for new drugs and 19 new drugs’ approval documents for clinical research. 9 clinical projects have been approved by experts and are put into industrial production.
Copyright:Herbridge Media
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
